Evidence map›Paper›PMID 41746155›Full record

ArticleArchives of endocrinology and metabolism2026

Non-invasive detection of metastatic papillary thyroid carcinoma after radical surgery using salivary metabolomic biomarkers.

Fei Yu, Jingya Pan, Liuting Zhang, Shaohua Li, Chuan Zhang, Jingjing Fu, Peng Zhou, Jun Wang, Xiaochen Yao, Yudan Ni and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fei YuNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jingya PanAffiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine Department of Thyroid and Breast Surgery Nanjing China Department of Thyroid and Breast Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine, Nanjing, China.
Liuting ZhangNanjing Medical University Department of Functional Examination Nanjing First Hospital Nanjing China Department of Functional Examination, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Shaohua LiNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Chuan ZhangNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jingjing FuNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Peng ZhouNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jun WangNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaochen YaoNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yudan NiNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ailing ZhangNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qingle MengNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rui YangNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Lei XuNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Feng WangNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jianhua WangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine Department of Thyroid and Breast Surgery Nanjing China Department of Thyroid and Breast Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine, Nanjing, China.
Liang ShiNanjing Medical University Department of Nuclear Medicine Nanjing First Hospital Nanjing China Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAccurate assessment of metastatic status is crucial for determining radioactive iodine (RAI) dosing in postoperative papillary thyroid carcinoma (PTC) patients. This study aimed to identify unbiased biomarkers in metastatic PTC patients after surgery by applying a metabolomics workflow in saliva samples. MATERIALS AND

methodsSaliva samples from 70 postoperative PTC patients (35 metastatic PTC patients in metastasis group and 35 non-metastatic PTC patients in control group) were analyzed using liquid chromatography - mass spectrometry. Orthogonal partial least-squares-discriminant analysis was applied to identify differential metabolites and significant pathways were examined within these metabolites. Receiver operating characteristic curve (ROC) analysis was utilized to further evaluate the diagnostic performance of candidate metabolites.

resultsA total of 119 differential metabolites were identified, with 108 upregulated and 11 downregulated. Pathway analysis revealed 13 significantly dysregulated metabolic pathways in metastatic PTC, including necroptosis, choline metabolism in cancer, sphingolipid signaling, valine, leucine and isoleucine biosynthesis, linoleic acid metabolism and pantothenate and CoA biosynthesis. ROC analysis demonstrated six discriminating biomarkers (5 lipids, 1 amine) that effectively distinguished metastatic from non-metastatic PTC, with all area under the curve values exceeding 0.8. Notably, these metabolites maintained diagnostic performance even in the thyroglobulin antibody-positive subgroup (≥ 4.11 IU/mL) for metastatic screening.

conclusionThis study demonstrates the potential of salivary biomarkers as a non-invasive diagnostic approach for metastatic PTC to aid the appropriate dosing for RAI therapy. It also offers new insights into the mechanisms of PTC metastasis and potential targets for adjuvant therapy.

Indexed as

metaboliteMetabolomicsmetastasispapillary thyroid carcinomasaliva

Identifiers

PMID41746155
PMCPMC12944297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.